Method of treating Crohn's Disease using sargramostim

Details Method of treating Crohn's Disease using sargramostim Method of treating Crohn's Disease using sargramostim

2005-04-06

2008-08-05

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07407931

ABSTRACT:
Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.

REFERENCES:
patent: 4961926 (1990-10-01), Gabrilove
patent: 5284656 (1994-02-01), Platz et al.
patent: 5468846 (1995-11-01), Ichikawa et al.
patent: 5606024 (1997-02-01), Boone et al.
patent: 5654186 (1997-08-01), Cerami
patent: 5762920 (1998-06-01), Yung et al.
patent: 5767156 (1998-06-01), Ferrante et al.
patent: 5790421 (1998-08-01), Osslund
patent: 5814308 (1998-09-01), Zhang
patent: 6020469 (2000-02-01), Hershenson
patent: 6037324 (2000-03-01), Schwender et al.
patent: WO 00 06080 (2000-02-01), None
patent: WO 00 47195 (2000-08-01), None
R. Leake, “Molecular Aspects of the GM-CSF Receptor: An Example of the Cell Signalling Mechanisms Used by Type 1 Cytokine Receptors”, European Journal of Cancer, vol. 35, Supp. 3, pp. S2-S3, 1999.
Roe et al. “Treatment of Chronic Inflammatory Disease in Glycogen Storage Disease Type 1 b with GM-CSF,”The New England Journal of Medicine, (1992), pp. 1666-1669, vol. 326, No. 25.
J. R. Korzenik et al., “Immunostimulation in Crohn's disease: Results of a pilot study of G-CSF (R-MethuG-SCF) in mucosal and fistulizing Crohn's disease”,Gastroenterology, (Apr. 2000) vol. 118, No. 4, Suppl. 2, part 1, pp. A874-A875 Abstract nr. 4852.
J.R. Korzenik et al., “Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease”,Digestive Diseases and Sciences(Jun. 2000) vol. 45, No. 6, pp. 1121-1129.
C.J. Bagley et al., “The structural and functional basis of cytokine receptor activation: Lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors”,Blood, (Mar. 1, 1997), vol. 89, No. 5, pp. 1471-1482.
J. R. Korzenik et al., “Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease”Gastroenterology, (Apr. 2001) vol. 120, No. 5, Suppl. 1, pp. A277-A278 Abstract nr. 1437.
B. Drumm et al., “Granulocyte-macrophage colony-stimulating factor for Crohn's disease”,The Lancet, (May 24, 2003) vol. 361, pp. 1830-1831.
B. Dieckgraefe et al. “Authors Reply”,The Lancet, (May 24, 2003) vol. 361, pp. 1830-1831.
D. Vaughan et al., “Treatment of Fistulas with Granulocyte Colony-Stimulating Factor in a Patient with Crohn's Disease”,N.E.J.M. (1999) vol. 340, pp. 239-240.

Affiliated with

Also associated with

Rating

Method of treating Crohn's Disease using sargramostim does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating Crohn's Disease using sargramostim, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating Crohn's Disease using sargramostim will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4000224